Antibiotics to prevent preterm birth

Submission date	Recruitment status No longer recruiting	Prospectively registered		
14/12/2007		☐ Protocol		
Registration date 18/12/2007	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
21/03/2013	Pregnancy and Childbirth			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Jim Neilson

Contact details

School of Reproductive and Developmental Medicine
University of Liverpool
1st floor, Liverpool Women's Hospital
Liverpool
United Kingdom
L8 7SS
+44 (0)151 702 4100
jneilson@liv.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 065810/Z/01/Z

Study information

Scientific Title

A randomised, community-based trial of Azithromycin for the Prevention of Pre-term Labour in Malawi

Acronym

APPLe

Study objectives

That routine antibiotic prophylaxis in a pregnant population with high burdens of infection, and high incidence of preterm birth, would reduce the incidence of prematurity.

Ethics approval required

Old ethics approval format

Ethics approval(s)

College Of Medicine Research Ethics Committee (COMREC), Blantyre (Malawi) approved in November 2003

Study design

Four centre placebo-controlled, randomised trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Preterm birth

Interventions

Azithromycin 1 g orally or placebo at 16 - 24 weeks and 28 - 32 weeks. For main trial, follow-up was to 6 weeks after birth. Children have been followed up to 18 months of age.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Azithromycin

Primary outcome measure

Preterm birth (less than 37 weeks gestation).

Secondary outcome measures

- 1. Mean gestational age at birth
- 2. Perinatal mortality
- 3. Birthweight
- 4. Malarial parasites at 28 32 weeks
- 5. Haemoglobin at 28 32 weeks

Overall study start date

01/02/2004

Completion date

31/07/2007

Eligibility

Key inclusion criteria

- 1. Pregnant women less than 24 weeks gestational age by ultrasound at recruitment
- 2. No age restriction, apart from age being compatible with pregnancy
- 3. Intention to remain within the district throughout pregnancy
- 4. Informed consent

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

2300

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

01/02/2004

Date of final enrolment

31/07/2007

Locations

Countries of recruitment

England

Malawi

United Kingdom

Study participating centre
School of Reproductive and Developmental Medicine
Liverpool
United Kingdom
L8 7SS

Sponsor information

Organisation

University of Liverpool (UK)

Sponsor details

Brownlow Hill Liverpool England United Kingdom L69 3BX jdowson@liv.ac.uk

Sponsor type

University/education

Website

http://www.liv.ac.uk/

ROR

https://ror.org/04xs57h96

Funder(s)

Funder type

Charity

Funder Name

The Wellcome Trust (UK) (grant ref: 065810)

Funder Name

Pfizer Inc. (USA) - supplied drug and placebo

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2009		Yes	No